AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Teva Pharmaceutical Industries Ltd. Earnings Release 2008

Apr 23, 2008

7082_rns_2008-04-23_1919e1fe-0ed6-4d59-9dd0-35e86904aed2.pdf

Earnings Release

Open in viewer

Opens in your device viewer

==> picture [198 x 48] intentionally omitted <==

Contact: Elana Holzman Teva Pharmaceutical Industries Ltd. 972 (3) 926-7554 Kevin Mannix Teva North America (215) 591-8912

FOR IMMEDIATE RELEASE

TEVA TO REPORT FIRST QUARTER 2008 FINANCIAL RESULTS ON MAY 6, 2008

CONFERENCE CALL SCHEDULED FOR 8:00 AM ET

Jerusalem, Israel, April 23, 2008 – Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it will release its first quarter 2008 financial results on Tuesday, May 6, 2008.

Teva will host a conference call and live webcast on that same day, at 8:00 am ET to discuss its first quarter 2008 results and overall business environment. A Question & Answer session will follow this discussion. The earnings release will be available on Teva’s web site at www.tevapharm.com prior to the call.

Investors and other interested parties may access a live webcast through Teva’s web site at www.tevapharm.com. Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software. Following the conclusion of the call, a replay of the webcast will be available within 24 hours at the Company’s web site. Alternatively, a replay of the call can be accessed until May 13, 2008 at 11:59 pm ET, by calling (201) 612-7415 outside the U.S. or (877) 660-6853 in the U.S. The Pass Code to access the replay is: Account #3055 and Conference ID #282223.

About Teva

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world's leading generic pharmaceutical company. The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 percent of Teva's sales are in North America and Europe.